is a UK-based startup founded in 2012 with a mission to prioritize patients in clinical research. The company's patient-first eClinical platform, designed in collaboration with patients and healthcare professionals, facilitates site-based to fully decentralized clinical, real-world, and post-marketing research. uMotif has earned the trust of global pharmaceutical companies, biotechs, CROs, and academic institutions, enabling the capture of extensive volumes of eCOA/ePRO, symptom, and wearable device data. The recent £20.00M Series B investment in May 25, 2022 was led by Albion VC, Athyrium Capital Management, and DNV GL, signifying investor confidence in uMotif's innovative approach to engaging patients and enhancing clinical trial outcomes. The company operates within the industries of Data Analytics, Health Care, IT, and Marketing. To learn more, visit their website at www.umotif.com.
